MENU
+Compare
GILD
Stock ticker: NASDAQ
AS OF
Dec 4, 04:17 PM (EDT)
Price
$123.11
Change
-$1.89 (-1.51%)
Capitalization
155.08B

GILD Gilead Sciences Forecast, Technical & Fundamental Analysis

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C... Show more

Industry: #Biotechnology
GILD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for GILD with price predictions
Dec 03, 2025

GILD's Stochastic Oscillator stays in oversold zone for 1 day

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in of 329 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 288 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 01, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GILD as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for GILD turned negative on December 01, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 58 similar instances when the indicator turned negative. In of the 58 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.199) is normal, around the industry mean (8.946). P/E Ratio (19.350) is within average values for comparable stocks, (24.032). Projected Growth (PEG Ratio) (0.228) is also within normal values, averaging (2.044). Dividend Yield (0.025) settles around the average of (0.027) among similar stocks. P/S Ratio (5.423) is also within normal values, averaging (3.663).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
GILD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

GILD is expected to report earnings to fall 23.48% to $1.89 per share on February 10

Gilead Sciences GILD Stock Earnings Reports
Q4'25
Est.
$1.89
Q3'25
Beat
by $0.32
Q2'25
Beat
by $0.05
Q1'25
Beat
by $0.04
Q4'24
Beat
by $0.19
The last earnings report on October 30 showed earnings per share of $2.47, beating the estimate of $2.15. With 1.25M shares outstanding, the current market capitalization sits at 155.08B.
A.I.Advisor
published Dividends

GILD paid dividends on September 29, 2025

Gilead Sciences GILD Stock Dividends
А dividend of $0.79 per share was paid with a record date of September 29, 2025, and an ex-dividend date of September 15, 2025. Read more...
A.I. Advisor
published General Information

General Information

a developer of therapeutic products and treatments for life threatening diseases

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Biotechnology
Address
333 Lakeside Drive
Phone
+1 650 574-3000
Employees
18000
Web
https://www.gilead.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LRNZ48.020.36
+0.75%
TrueShares Tech, AI and Deep Lrng ETF
SETM28.010.19
+0.68%
Sprott Critical Materials ETF
DGCB55.060.10
+0.18%
Dimensional Global Credit ETF
USHY37.480.06
+0.17%
iShares Broad USD High Yield Corp Bd ETF
JANM32.800.02
+0.07%
FT Vest U.S. Eq Max Buffr ETF - Jan

GILD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GILD has been loosely correlated with BMY. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then BMY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GILD
1D Price
Change %
GILD100%
+0.88%
BMY - GILD
48%
Loosely correlated
+5.62%
AMGN - GILD
45%
Loosely correlated
+2.09%
NVS - GILD
44%
Loosely correlated
+1.09%
ABBV - GILD
40%
Loosely correlated
+2.62%
GSK - GILD
40%
Loosely correlated
+1.45%
More